Pancreatic Cancer Research

ResearcherCold Spring Harbor LaboratoryActive in the last 2 years

Daniel Öhlund

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5847-2778; OpenAlex author ID A5020904122, A5116537255. Sources: OpenAlex.

Their work

Papers
37 (first author 5, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
125
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 5 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: 6 papers · 2026: 6 papers

Papers 37

  1. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00601-1↗
  2. New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer. Co-author DOI 10.1038/s41416-025-03295-9↗
  3. Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20191-5↗
  4. ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20304-0↗
  5. ASO Author Reflections: Understanding the Prognostic Role of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20312-0↗
  6. Unveiling sex differences in pancreatic ductal adenocarcinoma: Current evidence and future directions (Review). Co-author DOI 10.3892/ijo.2026.5848↗
  7. High prevalence of pancreatic steatosis in pancreatic cancer patients: A meta-analysis and systematic review. Co-author DOI 10.1016/j.pan.2024.11.010↗
  8. Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology. Co-author DOI 10.1038/s12276-024-01378-w↗
  9. A decade of patient-derived organoids in pancreatic cancer: points in translation. First author DOI 10.1080/00365521.2025.2555701↗
  10. Dissecting FAP+ Cell Diversity in Pancreatic Cancer Uncovers an Interferon-Response Subtype of Cancer-Associated Fibroblasts with Tumor-Restraining Properties. Last author DOI 10.1158/0008-5472.can-23-3252↗
  11. Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. Co-author DOI 10.1186/s12893-025-02983-w↗
  12. Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuv… Co-author DOI 10.3892/ol.2024.14845↗
  13. Can our experience with surveillance for inherited pancreatic cancer help to identify early pancreatic cancer in the general population? First author DOI 10.1007/s10689-024-00363-6↗
  14. Overcoming therapy resistance in pancreatic cancer: New insights and future directions. Last author DOI 10.1016/j.bcp.2024.116492↗
  15. Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3419↗
  16. Metabolomics for early pancreatic cancer detection in plasma samples from a Swedish prospective population-based biobank. Co-author DOI 10.21037/jgo-23-930↗
  17. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth. Co-author DOI 10.1158/1078-0432.ccr-22-0794↗
  18. Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-21-1088↗
  19. High throughput screen in a co-culture model to uncover therapeutic strategies to potentiate the cancer-inhibiting properties of the tumor-stroma in pancreatic… Last author DOI 10.1101/2022.03.11.483991↗
  20. A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer. Last author DOI 10.3390/ijms232112969↗
  21. Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits. Last author DOI 10.3389/fcell.2021.787485↗
  22. Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples. Co-author DOI 10.3390/cancers13215321↗
  23. Cancer Cell-Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/0008-5472.can-19-2578↗
  24. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Co-author DOI 10.3390/cancers12113234↗
  25. Novel prognostic markers within the CD44-stromal ligand network in pancreatic cancer. Co-author DOI 10.1002/cjp2.122↗
  26. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. Co-author DOI 10.1002/ijc.31900↗
  27. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Co-author DOI 10.1073/pnas.1908626116↗
  28. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Co-author DOI 10.1136/gutjnl-2018-316451↗
  29. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  30. VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival. Co-author DOI 10.1002/path.5141↗
  31. Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002124↗
  32. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Co-author DOI 10.1084/jem.20162024↗
  33. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2016.06.056↗
  34. Building up the tension between the epithelial and stromal compartment in pancreatic ductal adenocarcinoma. First author DOI 10.1038/cdd.2016.50↗
  35. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗
  36. Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma. First author DOI 10.3233/cbm-140430↗
  37. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. Co-author DOI 10.1186/1471-2407-13-154↗

Closest collaborators

The 25 strongest of 125 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Malin Sund · 15 shared papers, 2013–2026 · strength 2.40
  2. Oskar Franklin · 14 shared papers, 2013–2026 · strength 2.12
  3. Nils O. Elander · 5 shared papers, 2025–2026 · strength 1.20
  4. Hakon Blomstrand · 4 shared papers, 2025–2026 · strength 1.00
  5. Asif Halimi · 4 shared papers, 2025–2026 · strength 0.97
  6. Matthias J. Löhr · 3 shared papers, 2024–2026 · strength 0.81
  7. Jun Yoshino · 3 shared papers, 2026 · strength 0.77
  8. Hanna E. Seppänen · 3 shared papers, 2026 · strength 0.77
  9. Caj H. Haglund · 3 shared papers, 2026 · strength 0.77
  10. Ella Kesti · 3 shared papers, 2026 · strength 0.77
  11. David Arthur Tuveson · 9 shared papers, 2015–2024 · strength 0.75
  12. Christoph Springfeld · 2 shared papers, 2026 · strength 0.69
  13. John P. Neoptolemos · 2 shared papers, 2026 · strength 0.69
  14. Christoph W. Michalski · 2 shared papers, 2026 · strength 0.69
  15. Mariano Ponz‐Sarvisé · 6 shared papers, 2015–2025 · strength 0.62
  16. Joshua Cumming · 3 shared papers, 2022–2025 · strength 0.58
  17. Vincenzo Corbo · 5 shared papers, 2015–2025 · strength 0.58
  18. Thomas P. Hank · 2 shared papers, 2025–2026 · strength 0.56
  19. James E. Mason · 3 shared papers, 2021–2022 · strength 0.50
  20. Parniyan Maneshi · 2 shared papers, 2021–2025 · strength 0.45
  21. Ivonne Regel · 2 shared papers, 2020–2026 · strength 0.44
  22. Tobiloba E. Oni · 4 shared papers, 2015–2025 · strength 0.44
  23. Chang‐Il Hwang · 4 shared papers, 2015–2025 · strength 0.44
  24. Margarita Espona‐Fiedler · 2 shared papers, 2022–2024 · strength 0.44
  25. Bergþór Björnsson · 2 shared papers, 2025 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.